NovoFocus™ CR

Individuals who are carriers of hereditary pathogenic variants exhibit a higher risk (usually ≥50%) of developing cancers during their lifetime. These cancer-related variants are the predisposition to cancer. Therefore, early detection gives you opportunity to maximize health outcomes for your high-risk patients group with patient-tailored screening programs, preventive measures and proactive treatment.

Parameters

NovoFocus™ CR
Cancer Type	Multiple Cancers
Sample Type	≥ 5ml Blood
Turnaround Time	15 Calendar Days

Novogene Quality Assurance

Comprehensive Gene Coverage for Herediatary Cancer Screening

Through one sample and one test, NovoFocus™ CR can screen the whole exon regions of the genes which are recommended by international guidelines.

Advanced Technology

Using NGS platform and unique proprietary technology, assess the SNP, InDel, and large fragment deletions at once.

Authoritative Database

Integrated internationally recognized databases to interpret data and generate report.

Competitive Price

With top tier sequencing capacity and superior process efficiency, Novogene offers highly competitive prices for all our services.

Who Benefits from NovoFocus™ CR ?

Individuals with a positive family history (several generations) of same or different cancers.
Anyone who would like to find out more about their risk of developing cancer.

NovoFocus™ CR Workflow

NovoFocus™ CR contains 106 genes associated with hereditary cancers. The genes are carefully selected with the potential risks of developing one or more of the following hereditary tumors.

What Does NovoFocus™ CR Detect?

Associated Genes Across 8 Important Hereditary Cancer Types
Genes	Breast	Ovarian	Colorectal	Uterine	Renal	Pancreatic	Gastric	Prostate	Others
APC			●				●		●
ATM	●	●	●				●	●	●
AXIN2			●
BARD1	●
BRCA1	●	●		●		●	●	●
BRCA2	●	●				●	●	●	●
BRIP1	●	●
BUB1			●
BUB1B			●						●
BUB3			●
CDH1	●						●	●
CDKN2A						●			●
CHEK2	●		●		●			●	●
ELAC								●
EPCAM	●	●	●	●			●	●	●
FH					●
FLCN			●		●
HNF1A					●
HOXB13								●
MET					●
MLH1	●	●	●	●		●	●	●	●
MLH3			●	●					●
MSH2	●	●	●	●			●	●	●
MSH6		●	●	●			●	●	●
MUTYH			●
NBN	●	●						●
PALB2	●	●				●		●
PMS1			●
PMS2	●	●	●	●			●	●	●
PRSS1						●
PTEN	●		●	●			●		●
RAD51C	●	●						●
RAD51D	●	●						●
RNASEL								●
SDHA/SDHB					●				●
SDHC/SDHD					●				●
SMAD4			●				●
STK11	●	●	●	●		●	●		●
TP53	●		●		●		●		●
VHL					●	●			●

Data Interpretations

(*OMIM Database and NCCN Guidelines)

Positive Results	Uncertain Variants	Negative Results
Pathogenic/Likely pathogenic Medical Management Based on Recommendations for the Specific Variants	Uncertain Significance Variant Surveillance and Medical Management Based on Personal/Family Cancer History	Likely benign/Benign Recommendations based on general population cancer risk screening